180002-30-6

Basic information

• Product Name: 1H-Indene-1,6-diamine,2,3-dihydro-(9CI)
• Synonyms: 1H-Indene-1,6-diamine,2,3-dihydro-(9CI)
• CAS NO: 180002-30-6
• Molecular Formula: C9H12N2
• Molecular Weight: 148.20498
• Product Categories: AMINEPRIMARY
• Mol File: 180002-30-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Indene-1,6-diamine,2,3-dihydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indene-1,6-diamine,2,3-dihydro-(9CI)(180002-30-6)
• EPA Substance Registry System: 1H-Indene-1,6-diamine,2,3-dihydro-(9CI)(180002-30-6)

Safety Data

• Hazardous Substances Data: 180002-30-6(Hazardous Substances Data)

Upstream product

• 62658-54-2 6-nitro-indan-1-ylamine 
• 1159845-32-5 6-nitroindan-1-one azine 

Relevant articles and documents

Study on the synthesis, reduction and reductive amination of nitroindan-1-ones. Preparation of N-β-hydroxyethyl derivatives of 6-aminoindan-1-one and Indan-1,6-diamine

Synthesis of 6-aminoindan-1-one and 7-amino-5,6-dimethoxyindan-1-one by nitration of corresponding indanones, followed by selective palladium catalyzed reduction under mild conditions has been described. Reactions of the amines with oxirane leading to N.N-bis-(β-hydroxyethyl) derivatives were performed. The study of reductive amination of 6-nitroindan-1-one and 5,6-dimethoxy-7- nitroindan-1-one via azines to the corresponding amines as well as synthesis of N,N-bis-(β-hydroxyethyl) derivatives of the amines was also described.

Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase

A class of acetamidine derivatives of general formula (I) STR1 wherein R1 is hydrogen, C1-6 hydrocarbyl group optionally substituted by halo, halo, nitro, cyano or a group XR3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR4 wherein R4 is hydrogen or C1-6 alkyl; and R3 is hydrogen, C1-6 alkyl, or a group NR5 R6 wherein R5 and R6 are independently hydrogen or C1-6 alkyl, provided that R3 is not NR5 R6 when X is oxygen or S(O)n; R1a and R1b are independently selected from hydrogen and halo; R2 is a C1-14 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R2 being optionally substituted by one or more groups independently selected from halo; N3 ; nitro; CF3 ; ZR7 wherein Z is oxygen, C(O)m' wherein m' is 1 or 2, S(O)n' wherein n' is 0, 1 or 2, or a group NR8 wherein R8 is hydrogen or C1-6 alkyl and R7 is hydrogen, C1-6 alkyl or a group NR9 R10 wherein R9 and R10 are independently hydrogen or C1-6 alkyl; or R2 is substituted by a group (a) STR2 wherein R11 has a definition the same as for R1 ; with the proviso that when R1 is a C1-6 alkyl group and R2 is a C1-14 hydrocarbyl substituted by two groups ZR7 wherein one group ZR7 is CO2 H, the other group ZR7 is not NH2; and salts thereof, methods for the manufacture thereof, and therapies, particularly inhibtion of nitric oxide synthase, is disclosed.